Revolution Medicines Alleges Patent, Trade Secret, And False Comparison Claims Over ERAS-0015; Erasca Vows Strong Defense

On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed"). In the letter RevMed alleged that (1) the Company's asset ERAS-0015 is "substantially equivalent" to certain compositions claimed in RevMed's U.S. Patent No. 12,409,225 (the "‘225 Patent") and that ERAS-0015 infringes the ‘225 Patent under the doctrine of equivalents; (2) that a third party misappropriated RevMed's alleged trade secrets in connection with a patent relating to ERAS-0015, and that the Company is allegedly liable under the trade secret laws as a licensee; and (3) that the Company has improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures. RevMed demanded that, among other things, the Company immediately cease all making, using, offering for sale, selling, and importation of ERAS-0015 in the United States for any purpose not protected by the Hatch-Waxman safe harbor and cease making any deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236. The Company believes the assertions in the letter are without merit and intends to contest the allegations vigorously.